drugset / Trial / NCT07393542

A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma

NCT07393542

Phase 3 Recruiting 462 enrolled Suzhou Suncadia Biopharmaceuticals Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The study is being conducted to evaluate the efficacy of SHR-A2102 with adebrelimab versus gemcitabine in combination with cisplatin/carboplatin in previously untreated locally advanced or metastatic urothelial carcinoma.

Timeline

Start
2026-02-12
Primary completion
2027-09
Completion
2030-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Adebrelimab Monoclonal antibody
Comparator Carboplatin Small molecule
Comparator Cisplatin Other / unclassified
Comparator Gemcitabine Small molecule
Subject SHR-A2102 Other / unclassified

Indications